Intercept Pharms Inc Company Profile

What is the competitive landscape for INTERCEPT PHARMS INC

INTERCEPT PHARMS INC has one approved drug.

There are seven US patents protecting INTERCEPT PHARMS INC drugs.

There are one hundred and eighteen patent family members on INTERCEPT PHARMS INC drugs in thirty-seven countries and twelve supplementary protection certificates in eleven countries.

Summary for Intercept Pharms Inc

International Patents:	118
US Patents:	7
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Intercept Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		DISCN	Yes	No	10,751,349		Y
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		DISCN	Yes	No	RE48286		Y	Y
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		DISCN	Yes	No	10,174,073			Y
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		DISCN	Yes	No	10,047,117
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		DISCN	Yes	No	10,751,349		Y
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		DISCN	Yes	No	RE48286		Y	Y
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		DISCN	Yes	No	10,758,549

Expired US Patents for Intercept Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016	8,377,916
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016	7,138,390
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016	7,138,390
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016	8,058,267
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016	8,058,267
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016	8,377,916

International Patents for Intercept Pharms Inc Drugs

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	201590040
Japan	6978544
Chile	2015002145
Canada	3009149
South Korea	20170140325
Japan	6527077
South Korea	20150022974

Supplementary Protection Certificates for Intercept Pharms Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1392714	598	Finland
1392714	CR 2017 00025	Denmark		PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215
1392714	17C0003	France		PRODUCT NAME: ACIDE OBETICHOLIQUE; REGISTRATION NO/DATE: EU/1/16/1139 20161212
1392714	122017000034	Germany		PRODUCT NAME: OBETICHOLSAEURE; REGISTRATION NO/DATE: EU/1/16/1139 20161212
1392714	23/2017	Austria		PRODUCT NAME: OBETICHOLSAEURE, DESSEN PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE ODER AMINOSAEURE-KONJUGATE; REGISTRATION NO/DATE: EU/1/16/1139 20161212
1392714	300877	Netherlands		PRODUCT NAME: OBETICHOLZUUR; REGISTRATION NO/DATE: EU/1/16/1139 20161215
1392714	LUC00018	Luxembourg		PRODUCT NAME: ACIDE OBETICHOLIQUE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (OCALIVA); AUTHORISATION NUMBER AND DATE: EU/1/16/1139 20161215

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Intercept Pharms Inc
• Interpharm
• Interpharma Praha As
• Intersect Ent Inc

Intercept Pharmaceuticals Inc: Market Position, Strengths, and Strategic Insights

Last updated: February 20, 2026

What Is Intercept Pharmaceuticals Inc's Position in the Pharmaceutical Market?

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is a biotechnology firm focusing on developing and commercializing therapies targeting liver diseases. As of 2023, its product, obeticholic acid (OCA), is approved for the treatment of primary biliary cholangitis (PBC) and is under investigation for other liver conditions, including non-alcoholic steatohepatitis (NASH).

The company's market valuation stands around $2.8 billion, with revenue of approximately $595 million in 2022. It operates primarily in North America, with expanding presence in Europe and Asia. Its market share in PBC exceeds 85%, reflecting strong product adoption among specialists.

How Does Intercept Compare to Competitive Peers?

Key Competitors

Company	Focus Area	Leading Products	Market Cap (USD)	2022 Revenue (USD)	Clinical Pipeline Highlights
Gilead Sciences	Liver and Viral Diseases	Selonsertib (discontinued), Efruxiferm	$82.4B	$27.3B	Single-agent NASH trials
Genfit	Fibrosis, NASH	Elafibranor (clinical-stage)	~$735M	N/A within NASH	Phase 3 trials for NASH
Novartis	Multiple, including liver fibrosis	Selonsertib (discontinued)	$222.5B	$51.6B	Multiple pipeline compounds
Viking Therapeutics	NASH, Lipid Disorders	VK2809	~$670M	N/A	Phase 2b NASH data

Intercept surpasses peers in PBC market share but faces challenges in expanding into NASH. Its OCA product has a first-mover advantage supported by existing regulatory approvals.

Differentiators

• Regulatory Approvals: OCA has FDA and EMA approvals for PBC, with claims supported by Phase 3 data.

• Clinical Pipeline: Intercept is investing in OCA-based combination therapies and exploring NASH treatment options, with several Phase 2 and 3 trials underway.

• Intellectual Property: The company holds multiple patents covering formulations, dosing regimens, and potential combinatorial approaches to liver disease.

What Are the Strategic Strengths and Weaknesses of Intercept Pharmaceuticals?

Strengths

• Market Leadership in PBC: Dominates with over 85% market share, supported by regulatory approvals and clinician familiarity.

• Pipeline Focus: Expanding beyond PBC into NASH, with multiple late-stage trials designed to address a larger, more complex market.

• Pricing Power: Established reimbursement pathways in the US and Europe facilitate premium pricing for OCA.

Weaknesses

• Limited NASH Success: Previous trials for NASH failed to meet endpoints, leading to skepticism about pipeline prospects.

• Regulatory Risks: Additional approvals may require substantial evidence, and ongoing trials face potential delays or failures.

• Revenue Concentration: Heavy reliance on OCA sales for PBC, with limited diversification across other liver diseases.

What Are the Strategic Opportunities for Growth?

• NASH Market Expansion: Positive Phase 3 data could unlock significant revenue, as NASH markets are projected to reach $20 billion globally.

• Partnerships and Collaborations: Potential deals with pharma companies for combination therapies or pipeline expansion.

• Geographic Diversification: Greater focus on Asian markets, where rising liver disease prevalence presents growth prospects.

What Challenges Could Impede Long-term Success?

• Pipeline Failures: NASH trials are high-risk, with previous failures casting doubt on future outcomes.

• Competitive Innovation: Baru products may emerge with superior safety profiles or better efficacy, reducing OCA’s market dominance.

• Pricing and Reimbursement Environment: Increasing payer pressure globally could limit premium pricing strategies.

Key Takeaways

Intercept Pharmaceuticals Inc is a market leader in PBC, with a robust pipeline targeting future markets such as NASH. Its strength lies in regulatory approvals, market share, and product positioning. Risks include pipeline failures, competitive threats, and regulatory hurdles. Strategic focus on pipeline advancement and geographic expansion offers potential growth avenues, but execution risks remain significant.

Frequently Asked Questions

1. What is Intercept Pharmaceuticals’ main product?

Obeticholic acid (OCA) is Intercept's primary product, approved for primary biliary cholangitis (PBC) in the US and Europe.

2. How does Intercept’s pipeline compare to its competitors?

Intercept’s pipeline includes several Phase 2 and 3 trials for NASH and other liver conditions, but competitors like Gilead and Genfit have more advanced or broader pipelines, sometimes with more promising initial data.

3. What regulatory challenges does Intercept face?

Additional approvals for NASH and other indications require substantial clinical evidence. Past trials have failed to meet primary endpoints, increasing regulatory scrutiny.

4. How sustainable is Intercept’s market share in PBC?

High market share is supported by regulatory approval and clinician familiarity. However, any future generic entries or superior therapies could threaten this dominance.

5. What growth opportunities exist beyond liver diseases?

Expansion into Asian markets and exploration of combination therapies for NASH could drive future revenue streams.

References

[1] Intercept Pharmaceuticals Inc. (2023). Annual Report. Retrieved from https://www.interceptpharma.com/investors/sec-filings

[2] Gilead Sciences. (2022). Annual Financial Report. Retrieved from https://www.gilead.com/investors

[3] Genfit. (2022). Clinical Pipeline Overview. Retrieved from https://www.genfit.com

[4] Novartis. (2022). Annual Report. Retrieved from https://www.novartis.com/investors/financial-reporting

[5] MarketWatch. (2023). Liver Disease Therapeutics Market Analysis. Retrieved from https://www.marketwatch.com